Antiparasitic compounds

Abstract

The present invention relates to cyclopropylamide compounds that are useful in the treatment of parasitic infestations of animals. The compounds have the formula (I).

Description

FIELD OF THE INVENTION This invention relates to the use of cyclopropyl amide compounds, compositions and methods for controlling parasitic infestations of animals. BACKGROUND OF THE INVENTION A number of parasites are known to infest animals. These parasites can be great nuisances to both the animals and their owners. Treatment of animals to prevent infestation by parasites, or to reduce or control the proliferation of these parasites, especially ectoparasites of animals such as ticks in animals is thus important. The compounds currently available for parasite control and especially ectoparasite and tick control do not always demonstrate good efficacy, sufficiently quick onset of activity, or a long duration of action. Ectoparasites tend to irritate the animals and can also cause clinical disease and adverse sub-clinical conditions, either by themselves or by carrying vector-transmitted pathogens. Specifically, ticks parasitize on wild as well as domesticated animals and humans, and are known or suspected to be responsible for the transmission of pathogens including bacteria, viruses and protozoan parasites. Ticks also release toxins which cause inflammation or paralysis in the host. Occasionally, these toxins are fatal to the host. On the other hand, such ectoparasites seriously impact productivity in the livestock animal industry by reducing weight gain, or milk production, causing inferior quality hide, wool, and meat, and in some cases resulting in mortality. Ectoparasites are also responsible, in part, for the spread of pathogens as vectors and cause discomfort in livestock and companion animals impacting animal welfare. For example, a parasite which is prevalent among livestock animals, such as cattle, is the tick of the genus Rhipicephalus, especially those of the species R. microplus (tropical cattle tick), R. decoloratus and R. annulatus. Ticks such as R. microplus (formerly Boophilus microplus) are difficult to control because they lay eggs in the pasture where animals graze. Such limitations include toxicity and safety of existing compounds both for the animal and the user / owner, limited efficacy (potency, onset of activity and duration), narrow spectrum of parasiticide action, bioavailability, pharmacokinetics and pharmacodynamics challenges and resistance issues. Further, certain aspects of the invention overcome at least some limitations in the use of current parasiticides, particularly in providing effective long term, safe control of parasites, that are known to be difficult to treat. International patent applications WO2016 / 168056, WO2016 / 168058, WO 2016 / 168059 and WO2018 / 071327 disclose certain cyclopropyl amide compounds as having insecticidal and acaricidal activity and therefore, being useful in controlling agricultural plant pests. Although veterinary use is briefly mentioned, none of these citations exemplify or describe their use of the compounds as claimed herein that address at least some of the needs for its use of such compounds as veterinary medicament as described above. Furthermore, it was found that only a small selection of the compounds as described in these citation actually have an effect on veterinary parasites. SUMMARY OF THE INVENTION The present invention is related in a first aspect to a compound of Formula (I) r4 Formula (I) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein Ai is CR5, N=O, or N; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N ; wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R1 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cg)alkyl, S(Ci-C6)haloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-C6)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R5 is selected from the group consisting of H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci- C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)alkyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkenyl, (C3-Cs)halocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl),N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl),N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, CN, NO2, and =0; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Cgjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-Cs)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R11 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cg)alkyl, S(Ci-C6)haloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cg)haloalkyl, (Ci-C6)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-C6)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-C6)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-C6)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. Suitably the compounds of the invention and any embodiments thereof are for use in a method of treatment or control of a parasitic infestation of an animal, Suitably the compound and use according to invention and / or any embodiment thereof R1 is selected from the group consisting of H F, and Cl; R2 is selected from the group consisting of H, F, and Cl; R3 is selected from the group consisting of H, F, and Cl; R4 is selected from the group consisting of H, F, and Cl; R5 is selected from the group consisting of H F, Cl, Br, and I; R6 is selected from the group consisting of H, F, and Cl, Br, and CH3; R7 is selected from the group consisting of H F, Cl, Br, and I; R8 is selected from the group consisting of H, F, Cl, and Br, and CH3; R9 is selected from the group consisting of H F, Cl, Br, and I; R11 is H; R12 is selected from the group consisting H, F, CL, CH3, CF3; R13 is selected from the group consisting of H, F, Cl, CF3 and CH3; R14 is H or F; R15 is selected from the group consisting of H and CH3. Suitably the compound and use according to invention and / or any embodiment thereof R1 is H; R2 is selected from the group consisting of H, F, and Cl; R3 is selected from the group consisting of H, Cl, F, and Br; R4 is H, F, Cl; R5 is selected from the group consisting of H F, and Cl; R6 is selected from the group consisting of H, F, and Cl, and CH3; R7 is selected from the group consisting of H F, and Cl; R8 is selected from the group consisting of H, F, Cl, and CH3; R9 is selected from the group consisting of H F, and Cl; R11 is H; R12 is selected from the group consisting H, F and Cl; R13 is selected from the group consisting of H, F, and Cl; R14 is H; R15 is selected from the group consisting of H and CH3. Surprisingly it has been found that the compounds described in this application can be used as medicaments, especially as veterinary antiparasitic medicaments to treat or control parasite infestation of animals. The invention is understood to include compounds of the invention and / or embodiments thereof as described in this application for use as a medicament, especially a veterinary medicament, more preferably an antiparasitic veterinary medicament. The invention is also understood to include the use of compounds of the invention and / or embodiments thereof as described in this application in the manufacture of a medicament for the treatment or control of parasite infestation of animals. The invention is also understood to include the use of compounds of the invention and / or embodiments thereof as described in this application in the manufacture of a medicament for the protection of animals from parasite infestation. The compounds of the invention and / or embodiments thereof are suitably used in a method to treat or control an ectoparasite infestation. Suitably the compounds of the invention and / or embodiments thereof are used in a method, wherein the parasitic infestation is a tick infestation or flea infestation. The compounds are suitably used for a tick infestation. The compounds of the invention and / or embodiments thereof are suitably used against parasites wherein the parasite is a one host tick or a multi-host tick. Suitably the compounds of the invention are used against Rhipicephalus microplus. In a suitable use or method of the invention and / or any embodiment thereof, the animal is a warmblooded animal such as a mammal. Suitably, the compounds are also active in a livestock animal, such as a ruminant, bovine animal, or cattle. It was also found that the compounds are active in fish, against a sea lice infestation. Also the compounds are found active in a companion animal, such as a canine animal or a feline animal, especially a dog or cat. In a suitable use or method of the invention and / or any embodiment thereof, the animal is protected from a parasite infestation. Preferably an existing parasite infestation of the animal is treated or controlled. In a suitable use or method of the invention and / or any embodiment thereof, the method comprises administering the compound to an animal weekly, bi-weekly, monthly, every 6 weeks, every 2 months or every 3 months. The invention is also directed to a veterinary composition comprising an effective amount of a compound of Formula (l)-(XCII) as defined in any embodiment described herein and an inert carrier or formulation adjuvant. The composition is suitable for use in the treatment and control of a parasitic infestation of animals such as described herein. Suitably the veterinary composition is a topical composition, an oral composition, or an injection composition. BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows Plasma concentration of oily solution (Composition A) and volatile solution (Composition B) of compound 453. Figure 2 shows a comparison of concentrations of Compound 453 in the blood of cattle with no CPE (Composition C) and three different CPEs (Compositions D, E, and F) showing no significant improvement with the inclusion of any CPE. Figure 3 shows the duration of efficacy >90% against R. microplus and the onset of efficacy>90% against R.microplus for Composition G, H and Composition of Example 1. Figure 4: Structures of the compounds 1-480. DETAILED DESCRIPTION This detailed description of preferred embodiments is intended only to acquaint others skilled in the art with Applicants' invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This detailed description and its specific examples, while indicating preferred embodiments of this invention, are intended for purposes of illustration only. This invention, therefore, is not limited to the preferred embodiments described in this specification and may be variously modified. In addition, for conciseness purposes and readability only some combinations of embodiments are explicitly described, however it should be understood that other combinations of embodiments are also contemplated. Briefly, this invention relates to compounds that can generally be used as active ingredient in a medicament for animals. The compounds of the invention and / or embodiments thereof are suitably used in a method to treat or control an ectoparasite infestation and / or to protect animals from parasite infestations. Surprisingly, it has been found that the compounds of the invention and / or embodiments thereof described herein exhibit superior broad-spectrum efficacy against harmful parasites more rapidly, and over a long duration compared to other similar compounds known in the art when administered to an animal in need thereof. Therefore, these compounds are useful in the methods or uses of the invention and / or embodiments thereof. In the following text the compounds for use according to the invention and / or embodiments thereof are described as "compounds of the invention" or "compounds" or "compounds of the invention and / or embodiments thereof (including compounds of Formula (1)" or "compounds of formula (1)" when they are disclosed as compounds per se or as compounds for use / in the method according to the invention. The unexpected broad parasiticidal properties of these compounds for use according to the invention and / or embodiments thereof are of considerable significance since there are few agricultural pesticides that can be effectively be used against ectoparasites of animals, let alone against a broad range of animal parasites and in various target species Compounds of the invention and / or embodiments thereof including compounds of Formula (l)-(XCII) show desirable bioavailability and pharmacokinetics when using different administration routes to administer them as a medicament to animals.. Many of the compounds also provide desirable safety profiles toward the target host animal and / or their owners. In addition, it has been discovered that a single administration of such compounds generally provides potent activity against a broad range of ectoparasites, including difficult to treat parasite infestations, using relevant administration routes while also tending to provide fast onset of activity, and / or long duration of activity, and / or desirable safety profiles. Consequently, these compounds have been shown to be useful as medicaments, especially antiparasitic veterinary medicaments. The compounds of the invention and / or embodiments thereof show desired beneficial properties, that makes their use in medicaments for animals suitable and it has been further shown that the resistance breaking properties of such compounds are very favorable. The Examples show that compounds of the invention and / or embodiments thereof including compounds of Formula (I) have broad activity both in vitro and in vivo against a number of veterinary relevant parasites that affect animals, such as one -host and multi- host ticks, fleas, bed bugs and sea lice that belong to diverse classes of biological organisms that are veterinary relevant parasites. It has been further shown in the Examples that existing parasite infestation with such parasites in different animals (cattle, dogs, fish, guinea pigs) can be successfully treated, while being safe to the animal. Furthermore, the examples show that the compounds of the invention and / or embodiments thereof act against a broad range of animal parasites, in particular ectoparasites when administered to various target animals using a variety of administration routes. Consequently, by using the compounds of the invention and / or embodiments thereof as described in this application disadvantages of the prior art can be avoided, because a convenient, safe administration of the cyclopropyl amide compound would be sufficient to achieve the desired effect. In a first aspect the invention is directed to a compound of Formula (I) R4 Formula (I) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein Ai is CR5, N=O, or N; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N; and wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. It was found that compounds wherein the ring formed by C-A1-A2-A3-A4-A5 is substituted with at least one halogen, these compounds are active against animal ectoparasites. This is in contrast to compounds wherein the ring formed by C-A1-A2-A3-A4-A5 is not substituted with at halogen. The comparative example below shows that similar compounds have been tested in prior art documents WO2016 / 168059 and WO2018 / 071327 against a range of agrochemical relevant parasites. Many compounds from WO2016 / 168059 and WO2018 / 071327 that were active in plant protection assays, were not active against animal parasites in an assay as described in Example 1. It was found that compounds wherein the ring formed by A1-A5 that did not have a halogen substitution were active against agrochemical parasites but not against animal parasites. Compounds wherein the ring formed by A1-A5 is substituted by at least one halogen are active against animal parasites. In the first aspect the compounds according to the invention are further defined as follows R1 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cg)alkyl, S(Ci-C6)haloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-C6)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R5 is selected from the group consisting of H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkenyl, (C3-Cs)halocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci<6)alkyl)(C(=O)O(Ci<6)alkyl), N((CX-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-C6)cycloalkyl, (C3-Cs)halocycloalkenyl, (C3-Cs)halocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci<6)alkyl)(C(=O)O(Ci<6)alkyl), N((CX-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-C6)cycloalkyl, (C3-Cs)halocycloalkenyl, (C3-Cs)halocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci<6)alkyl)(C(=O)O(Ci<6)alkyl), N((CX-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci- C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)alkyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkenyl, (C3-Cs)halocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl),N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl),N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Cgjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-Cs)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R11 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci- Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy(Ci-Cg)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cg)alkoxyC(=O)(Ci-C6)alkyl H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, R1 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (C3-Cs)cycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (C3-Cs)halocycloalkenyl, (Ci-Cs)haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R1 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R1 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Ci-Cs)haloalkyl of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Ci-C6)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R1 is H. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, ( (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, (Ci-C6)alkyl-S(O)2NH2, (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy, and S-(Halo)5. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkoxy, and S-(Halo)5. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting of H, F, Cl, Br, CN, (Ci-Cs)alkyl, (Ci-Cs)haloalkyl and S-(Halo)5. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting of H, F, Cl, Br, CN, CH3, CHF2, CF3, OCHF2 and S-(Halo)5. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting of H, F, Cl. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, R2 is Cl. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs)haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R2 is selected from the group consisting of H, F, Cl, and Br. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, ((C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, (Ci-C6)alkyl-S(O)2NH2, (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-C6)haloalkenyl, and (Ci-Cs) haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, Cl, Br, I, CH3, CF3, CHF2, OCF3, OCH3, CH=CHF, CeC, CH=CH2. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, Cl, Br. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, and Cl. In an embodiment of the invention and / or embodiments thereof, R3 is H or F. In an embodiment of the invention and / or embodiments thereof, R3 is H. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-C6)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-C6)haloalkenyl, and (Ci-Cs) haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-C6)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R3 is selected from the group consisting of H, F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, ((C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy, and S-(Halo)5. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, Cl, Br, (Ci-C6)alkyl, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl (Ci-Cs)alkoxy, (C2-C6)haloalkenyl, and S-(Halo)5. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, Cl, Br, CH3, CF3, OCH3, CH=CHF, C=C, CH=CH2and SF5. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, Cl, and Br. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, and Cl. In an embodiment of the invention and / or embodiments thereof, R4 is Cl. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, and (C2-Cs)haloalkenyl. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R4 is selected from the group consisting of H, F, Cl, Br. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-C6)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-C6)alkyl, NH(Ci-C6)alkenyl, NH(Ci-C6)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)O(Ci-Cs)alkyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-Cs)alkyl, NH(Ci-C6)alkenyl, NH(CX-C6)alkynyl, NH-C(=O)O(Ci-C6)alkyl. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-C6)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of H, F, Cl, Br, I, CH3, OCH3, and CF3. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of H, F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of H, F, and Cl. In an embodiment of the invention and / or embodiments thereof, R5 is H or F. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-C6)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of H, F, Cl, CN, NO2, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R5 is selected from the group consisting of H, F, Cl, CN and (Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkyl, (Cs-Csjhalocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-C6)alkyl, NH(Ci-C6)alkenyl, NH(Ci-C6)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-C6)alkyl), NH-C(=0)0(Ci-C6)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)O(Ci-Cs)alkyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-Cs)alkyl, NH(Ci-C6)alkenyl, NH(Ci-C6)alkynyl, NH-C(=O)O(Ci-C6)alkyl. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-C6)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, and (C2-Cs)haloalkenyl. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, Cl, Br, I, CH3, OCH3, CH=CHF, CH=CH, and CF3. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, Cl, Br, I, CH3, OCH3, CH=CHF, CH=CH, and CF3. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, Cl, Br, and CH3. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, Cl, and CH3. In an embodiment of the invention and / or embodiments thereof, R6 is H or F. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-C6)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, Cl, NH(Ci-C6)alkyl, (Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, NH(Ci-C6)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)lR10. In an embodiment of the invention and / or embodiments thereof, R6 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-C6)alkyl, NH(Ci-C6)alkenyl, NH(Ci-C6)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(0)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)O(Ci-Cs)alkyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-Cs)alkyl, NH(Ci-C6)alkenyl, NH(CX-C6)alkynyl, NH-C(=O)O(Ci-C6)alkyl. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-C6)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, and (C2-Cs)haloalkenyl. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of H, F, Cl, Br, I, CH3, OCH3, CH=CHF, CH=CH, and CF3. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of H, F, Cl, Br, I, CH3, OCH3, CH=CHF, CH=CH, and CF3. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of H, F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of H, F, and Cl. In an embodiment of the invention and / or embodiments thereof, R7 is H or F. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-C6)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R7 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-C6)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-C6)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-C6)alkyl, NH(Ci-C6)alkenyl, NH(Ci-C6)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-C6)alkylphenyl, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)O(Ci-Cs)alkyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-Cs)alkyl, NH(Ci-C6)alkenyl, NH(CX-C6)alkynyl, NH-C(=O)O(Ci-C6)alkyl. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of H, F, Cl, Br, I, (Ci-C6)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, and (C2-C6)haloalkenyl. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of H, F, Cl, Br, I, CH3, OCH3, CH=CHF, CH=CH, and CF3. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of H, F, Cl, Br, I, CH3, OCH3, CH=CHF, CH=CH, and CF3. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of H, F, Cl, Br, and CH3. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of H, F, Cl, and CH3. In an embodiment of the invention and / or embodiments thereof, R8 is H or F. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of H, F, Cl, NH(Ci-C6)alkyl, and (Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R8 is selected from the group consisting of H, F, and NH(Ci-C6)alkyl. In an embodiment of the invention and / or embodiments thereof, R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-C6)alkyl, (Cr Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkyl, (Cs-Csjhalocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-C6)alkyl, NH(Ci-C6)alkenyl, NH(Ci-C6)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl. In an embodiment of the invention and / or embodiments thereof, R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkyl, C(=O)(Ci-Cs)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)O(Ci-Cs)alkyl, N((Ci-C6)alkyl)2, NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-Cs)alkyl, NH(Ci-C6)alkenyl, NH(CX-C6)alkynyl, NH-C(=O)O(Ci-C6)alkyl. Compound and use according to any of the preceding claims, wherein R9 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-C6)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, R9 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)alkenyl, and (C2-Cgjhaloalkenyl. In an embodiment of the invention and / or embodiments thereof, R9 is selected from the group consisting of H, F, Cl, Br, I, CH3, OCH3, CH=CHF, CH=CH, and CF3. In an embodiment of the invention and / or embodiments thereof, R9 is selected from the group consisting of H, F, Cl, Br, I, CH3, OCH3, CH=CHF, CH=CH, and CF3. In an embodiment of the invention and / or embodiments thereof, R9 is selected from the group consisting of H, F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, R9 is selected from the group consisting of H, F, and Cl. In an embodiment of the invention and / or embodiments thereof, R9 is H or F. In an embodiment of the invention and / or embodiments thereof, R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -O-. In an embodiment of the invention and / or embodiments thereof, R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-. In an embodiment of the invention and / or embodiments thereof, the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN. In an embodiment of the invention and / or embodiments thereof, the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, and Cl. In an embodiment of the invention and / or embodiments thereof, the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl. In an embodiment of the invention and / or embodiments thereof, the ring formed by R6 and R7 is not substituted. In an embodiment of the invention and / or embodiments thereof, R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-. In an embodiment of the invention and / or embodiments thereof, R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-. In an embodiment of the invention and / or embodiments thereof, the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, and CN. In an embodiment of the invention and / or embodiments thereof, the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, and Cl. In an embodiment of the invention and / or embodiments thereof, the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl. In an embodiment of the invention and / or embodiments thereof, the ring formed by R7 and R8 is not substituted. In an embodiment of the invention and / or embodiments thereof, R10 is selected from the group consisting H, (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, ((Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl, and (Ci-Cs)alkylphenyl. In an embodiment of the invention and / or embodiments thereof, R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl. In an embodiment of the invention and / or embodiments thereof, R11 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy, and (Ci-Cs)alkyl-S(O)2NH2. In an embodiment of the invention and / or embodiments thereof, R11 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, and (Ci-Cg)alkyl. In an embodiment of the invention and / or embodiments thereof, R11 is selected from the group consisting of H, F, Cl, Br, I, and CH3. In an embodiment of the invention and / or embodiments thereof, R11 is selected from the group consisting of H, F, Cl, and CH3. In an embodiment of the invention and / or embodiments thereof, R11 is H. In an embodiment of the invention and / or embodiments thereof, R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy, and (Ci-Cs)alkyl-S(O)2NH2. In an embodiment of the invention and / or embodiments thereof, R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl; (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs)haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R12 is selected from the group consisting of H, F, Cl, Br, I, (Ci-C6)alkyl, (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R12 is selected from the group consisting of H, F, Cl, CH3 and CF3. In an embodiment of the invention and / or embodiments thereof, R12 is H or F. In an embodiment of the invention and / or embodiments thereof, R12 is H. In an embodiment of the invention and / or embodiments thereof, R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (C2- C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy, (Ci-Cs)alkyl-S(O)2NH2 and triazolyl. In an embodiment of the invention and / or embodiments thereof, R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs)haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R13 is selected from the group consisting of H, F, Cl, Br, I, (Ci-C6)alkyl, and (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R13 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R13 is selected from the group consisting of H, F, Cl, CH3 and CF3. In an embodiment of the invention and / or embodiments thereof, R13 is Cl or F. In an embodiment of the invention and / or embodiments thereof, R13 is Cl. In an embodiment of the invention and / or embodiments thereof, R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy, and (Ci-Cs)alkyl-S(O)2NH2. In an embodiment of the invention and / or embodiments thereof, R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs)haloalkoxy. In an embodiment of the invention and / or embodiments thereof, R14 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R14 is selected from the group consisting of H, F, Cl, CH3 and CF3. In an embodiment of the invention and / or embodiments thereof, R14 is selected from the group consisting of H and F. In an embodiment of the invention and / or embodiments thereof, R14 is H. In an embodiment of the invention and / or embodiments thereof, R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, and (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R15 is selected from the group consisting of H, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl. In an embodiment of the invention and / or embodiments thereof, R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, R15 is selected from the group consisting of H, and CH3. In an embodiment of the invention and / or embodiments thereof, R15 is H. In an embodiment of the invention and / or embodiments thereof, R1 is selected from the group consisting of H F, and Cl; R2 is selected from the group consisting of H, F, and Cl; R3 is selected from the group consisting of H, F, and Cl; R4 is selected from the group consisting of H, F, and Cl; R5 is selected from the group consisting of H F, Cl, Br, and I; R6 is selected from the group consisting of H, F, and Cl, Br, and CH3; R7 is selected from the group consisting of H F, Cl, Br, and I; R8 is selected from the group consisting of H, F, Cl, and Br, and CH3; R9 is selected from the group consisting of H F, Cl, Br, and I; R11 is H; R12 is selected from the group consisting H, F, CL, CH3, CF3; R13 is selected from the group consisting of H, F, Cl, CF3 and CH3; R14 is H or F; and R15 is selected from the group consisting of H and CH3. In an embodiment of the invention and / or embodiments thereof, R1 is H; R2 is selected from the group consisting of H, F, and Cl; R3 is selected from the group consisting of H, Cl, F, and Br; R4 is H, F, Cl; R5 is selected from the group consisting of H F, and Cl; R6 is selected from the group consisting of H, F, and Cl, and CH3; R7 is selected from the group consisting of H F, and Cl; R8 is selected from the group consisting of H, F, Cl, and CH3; R9 is selected from the group consisting of H F, and Cl; R11 is H; R12 is selected from the group consisting H, F and Cl; R13 is selected from the group consisting of H, F, and Cl; R14 is H; R15 is selected from the group consisting of H and CH3. In an embodiment of the invention and / or embodiments thereof, R1 is H; R2 is selected from the group consisting of H, F, and Cl; R3 is selected from the group consisting of H, Cl, F, and Br; R4 is H, F, Cl; R5 is selected from the group consisting of H F, and Cl; R6 is selected from the group consisting of H, F, and CH3; R7 is selected from the group consisting of H F, and Cl; R8 is selected from the group consisting of H, F, and CH3; R9 is selected from the group consisting of H F, and Cl; R11 is H; R12 is selected from the group consisting H, and F; R13 is selected from the group consisting of F and Cl; R14 is H; R15 is selected from the group consisting of H and CH3. In an embodiment of the invention and / or embodiments thereof, at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, and Br. In an embodiment of the invention and / or embodiments thereof, at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, at least one of R5, R6, R7, R8, R9, is F. In an embodiment of the invention and / or embodiments thereof, at least two of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, and Br. In an embodiment of the invention and / or embodiments thereof, at least two of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, at least two of R5, R6, R7, R8, R9, is F. In an embodiment of the invention and / or embodiments thereof, at least one of R5, R6, R7 is a substituent selected from the group consisting of F, Cl, and Br. In an embodiment of the invention and / or embodiments thereof, at least one of R5, R6, R7 is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, at least one of R5, R6, R7 is F. In an embodiment of the invention and / or embodiments thereof, at least one of R5, R7 is a substituent selected from the group consisting of F, Cl, and Br. In an embodiment of the invention and / or embodiments thereof, at least one of R5, R7 is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, at least one of R5, R7 is F. In an embodiment of the invention and / or embodiments thereof, R5 and R7 are each a substituent selected from the group consisting of F, Cl, and Br. In an embodiment of the invention and / or embodiments thereof, R5 and R7 are each a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, R5 and R7 are each F. In an embodiment of the invention and / or embodiments thereof, 0,1 or 2 of Ai, A2, A3, A4, A5 is N In an embodiment of the invention and / or embodiments thereof, the compound is a prodrug and at least one of Ai, A2, A3, A4, A5 is N=O. In an embodiment of the invention and / or embodiments thereof, 0, 1 or 2 of Ai, A2, A3, A4, A5 is N=O In an embodiment of the invention and / or embodiments thereof, Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein no more than 3 of Ai, A2, A3, A4, A5 are N. In an embodiment of the invention and / or embodiments thereof, Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein 0 or 1 of Ai, A2, A3, A4, A5 are N. In an embodiment of the invention and / or embodiments thereof, Ai is CR5 or N; A2 is CRg or N A3 is CR?; A4 is CRg; As is CRg; wherein 0 or 1 of Ai, or A2 are N. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (II) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I, wherein R2, R3, R4, R5, R6, R7, R8, R9 R12, R13, R14, R15, Ai, A2, A3, A4, and A5 are defined as elsewhere in this description. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (II) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein Ai is CR5, N=O, or N; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N ; wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R5 is selected from the group consisting of H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl), N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl)(C(=O)(C1-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci- C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6)halocycloalkenyl, (C3-C6)halocycloalkyl, (Ci-C6)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci<6)alkyl)(C(=O)O(Ci<6)alkyl), N((CX-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci<6)alkyl)(C(=O)O(Ci<6)alkyl), N((CX-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, CN, NO2, and =0; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Cgjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Csjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-Cs)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (C3-Cg)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (II) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; Ai is CR5, N=O, or N, A2 is CRs, N=O, or N A3 is CR7, N=O, or N A4 is CRg, N=O or N A5 is CRg, N=O or N wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cg)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, CN; R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, and CN; R9 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R10 is selected from the group consisting H, (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, ((Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl, and (Ci-Cs)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFs; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (II) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)aIkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein no more than 3 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, and N(Ci-C6)alkyl-C(=O)IR10; R6 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-C6)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and (Ci-Cs)haloalkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, and Cl; R8 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, and Cl; R9 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cg)alkyl, (Ci-C6)alkyloxy-(Ci-C6)alkyl, (C2-Cg)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFs; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (II) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein 0 or 1 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, CN, NO2, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, NH(Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, and Cl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R8 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R9 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is H or F ; R13 is Cl or F ; R14 is selected from the group consisting of H and F ; R15 is selected from the group consisting of H, and CH3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (II) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; Ai is CR5 or N; A2 is CRs or N; A3 is CR?; A4 is CRg; As is CRg; wherein 0 or 1 of Ai, or A2 are N; R5 is selected from the group consisting of H, F, Cl, CN and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, and NH(Ci-Cg)alkyl; R7 is selected from the group consisting of H, and F ; R8 is selected from the group consisting of H, and F ; R9 is selected from the group consisting of H and F ; R12 is H ; R13 is Cl; R14 is H; R15 is H; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (III) H 5 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2, R3, R4, R5, R6, R7, R8, R9 R13, R14, R15, Ai, A2, A3, A4, and A5 are defined as elsewhere in this description, 10 wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (III) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein Ai is CR5, N=O, or N; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N ; wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (Cg-Csjcycloalkyl, (C2-Cs)alkenyl, (Cg-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cg-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cg-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cg-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cg-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cg-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cg-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cg-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cg-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cg-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cg-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R5 is selected from the group consisting of H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cg-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cg-Csjhalocycloalkenyl, (Cg-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl), N((C1-C6)alkyl)(C(=O)(C1-C6)alkyl-O(C1-C6)alkyl), N((C1-C6)alkyl)(C(=O)(C1-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((C1-C6)alkylC(=O)(C1-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)lR10 NH(Ci-Cs)alkyl, NH(Ci-C6)alkenyl, NH(Ci-C6)alkynyl, NH(Ci-C6)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)alkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cg-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cg-Csjhalocycloalkenyl, (Cg-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, CN, NO2, and =0; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Cgjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (C3-C6)halocycloalkenyl, (C3-C6)halocycloalkyl, (Ci-C6)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-Cs)alkyl)(Ci-Cs)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Cgjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-C6)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, (C3-C6)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (III) H and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; Ai is CR5, N=O, or N, A2 is CRs, N=O, or N A3 is CR7, N=O, or N A4 is CRg, N=O or N A5 is CRg, N=O or N wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN; R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, and CN; R9 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R10 is selected from the group consisting H, (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, ((Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl, and (Ci-C6)alkylphenyl; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (III) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-C6) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein no more than 3 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, and N(Ci-C6)alkyl-C(=O)IR10; R6 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, and (Ci-Cs)haloalkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Cgjalkyl, F, and Cl; R8 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, and Cl; 5 R9 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; 10    R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. 15 In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (III) R4 R3\              Cl Cl and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, 20 wherein R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; Ai is CR5 or N; 25 A2isCRsorN; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein 0 or 1 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, CN, NO2, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, NH(Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, and Cl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R8 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R9 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R13 is Cl or F ; R14 is selected from the group consisting of H and F ; R15 is selected from the group consisting of H, and CH3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (III) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; Ai is CR5 or N; A2 is CRs or N; A3 is CR?; A4 is CRg; As is CRg; wherein 0 or 1 of Ai, or A2 are N; R5 is selected from the group consisting of H, F, Cl, CN and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R7 is selected from the group consisting of H, and F ; R8 is selected from the group consisting of H, and F ; R9 is selected from the group consisting of H and F ; R13 is Cl; R14 is H; R15 is H; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IV) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein 5    R2, R3, R4, R5, R6, R7, R8, R9 R12, R13, R14, Ai, A2, A3, A4, and A5 are defined as elsewhere in this description and wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a 10 compound of formula (IV) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein 15 Ai is CR5, N=O, or N; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N ; wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R5 is selected from the group consisting of H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-Cs)alkyl)(Ci-Cs)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci- C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)alkyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkenyl, (C3-Cs)halocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl),N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl),N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-C6)alkenyl, (C2-C6)alkynyl, (C2-C6)haloalkenyl, (C3-C6)cycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-Cs)alkyl)(Ci-Cs)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkenyl, (C3-Cs)halocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Cgjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-Cs)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (C3-Cs)cycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IV) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; Ai is CR5, N=O, or N, A2 is CR6, N=O, or N A3 is CR7, N=O, or N A4 is CRg, N=O or N A5 is CRg, N=O or N wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN; R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, and CN; R9 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R10 is selected from the group consisting H, (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, ((Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl, and (Ci-C6)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFs; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IV) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-C6) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein no more than 3 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, and N(Ci-C6)alkyl-C(=O)IR10; R6 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and (Ci-Cs)haloalkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Ca)alkyl, F, and Cl; R8 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Ca)alkyl, F, and Cl; R9 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IV) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein 0 or 1 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, CN, NO2, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, NH(Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, and Cl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R8 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R9 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is H or F ; R13 is Cl or F ; R14 is selected from the group consisting of H and F ; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IV) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; Ai is CR5 or N; A2 is CRs or N; A3 is CR7; A4 is CRg; As is CRgJ wherein 0 or 1 of Ai, or A2 are N; R5 is selected from the group consisting of H, F, Cl, CN and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; 5 R7 is selected from the group consisting of H, and F ; R8 is selected from the group consisting of H, and F ; R9 is selected from the group consisting of H and F ; R12 is H ; R13 is Cl; 10    R14 is H; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a 15 compound of formula (V) R4 R3\              Cl Cl and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein 20    R2, R3, R4, R5, R6, R7, R8, R9 R12, R13, R15, Ai, A2, A3, A4, and A5 are defined as elsewhere in this description and wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. 25 In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (V) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein Ai is CR5, N=O, or N; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N ; wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (C3-C6)cycloalkenyl, (C2-Cs)alkynyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, (C3-C6)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R5 is selected from the group consisting of H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci- C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(0)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci- C6)al kyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-C6)alkylphenyl, (Ci-C6)alkyl-S(O)2NH2, (Ci-C6)haloalkoxy, (Ci-C6)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(CX-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, CN, NO2, and =0; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Cgjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Csjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-Cs)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (C3-Cg)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (V) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; Ai is CR5, N=O, or N; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N; wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -O-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN; R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, and CN; R9 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-Cg)alkenyl, (C2-Cg)haloalkenyl, and C(=O)-O-(Ci-Cg)alkyl; R10 is selected from the group consisting H, (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, ((Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl, and (Ci-C6)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFs; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, and Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (V) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein no more than 3 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, and N(Ci-Cg)alkyl-C(=O)lR10; R6 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-C6)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, and (Ci-Cs)haloalkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, and Cl; R8 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Cgjalkyl, F, and Cl; R9 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (V) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein 0 or 1 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, CN, NO2, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, NH(Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, and Cl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R8 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R9 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is H or F ; R13 is Cl or F ; R14 is selected from the group consisting of H and F ; R15 is selected from the group consisting of H, and CH3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (V) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; Ai is CR5 or N; A2 is CRs or N; A3 is CR7; A4 is CRg; As is CRgJ wherein 0 or 1 of Ai, or A2 are N; R5 is selected from the group consisting of H, F, Cl, CN and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; 5 R7 is selected from the group consisting of H, and F ; R8 is selected from the group consisting of H, and F ; R9 is selected from the group consisting of H and F ; R12 is H ; R13 is Cl; 10    R14 is H; R15 is H wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. 15 In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VI) R4 R3\              Cl Cl and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, 20 wherein R2, R3, R4, R5, R6, R7, R8, R9 R13, Ai, A2, A3, A4, and A5 are defined as elsewhere in this description and wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a 25 compound of formula (VI) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein Ai is CR5, N=O, or N; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N ; wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cg)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cg)alkynyl, (Ci-Cs)alkoxy, (Ci-Cg)haloalkyl, (Cs-Cgjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R5 is selected from the group consisting of H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl), N((C1-C6)alkyl)(C(=O)(C1- C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-C6)alkenyl, (C2-Cs)alkynyl, (C2-C6)haloalkenyl, (C3-C6)cycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, CN, NO2, and =0; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Cgjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Csjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-Cs)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VI) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; Ai is CR5, N=O, or N; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N; wherein no more than 3 of Ai, A2, A3, A4, A5 are N or N=O; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Ca)alkyl, F, Cl, Br, I, CN; R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, and CN; R9 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R10 is selected from the group consisting H, (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, ((Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl, and (Ci-Cs)alkylphenyl; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, and Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VI) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-C6) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein no more than 3 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, and N(Ci-C6)alkyl-C(=O)IR10; R6 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, and (Ci-Cs)haloalkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Cgjalkyl, F, and Cl; R8 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, and Cl; 5 R9 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; 10 wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VI) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; Ai is CR5 or N; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein 0 or 1 of Ai, A2, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, CN, NO2, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, NH(Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, and Cl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R8 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R9 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R13 is Cl or F ; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VI) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; Ai is CR5 or N; A2 is CRs or N; A3 is CR7; A4 is CRg; As is CRg; wherein 0 or 1 of Ai, or A2 are N; R5 is selected from the group consisting of H, F, Cl, CN and (Ci-Cs)alkyl; R6 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R7 is selected from the group consisting of H, and F ; R8 is selected from the group consisting of H, and F ; R9 is selected from the group consisting of H and F ; 5     R13 is Cl; wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. 10 In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VII) R4 R3<                Cl       Cl                                            H and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, 15 wherein wherein R2, R3, R4, R12, R13, R14, R15, are defined as elsewhere in this description. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cg)haloalkenyl, (C3-C6)halocycloalkenyl, (Ci-Cg)haloalkoxy, S(Ci-Cg)alkyl, S(O)(Ci-Cg)alkyl, S(O)2(Ci-Cs)alkyl, SfCi-CgJhaloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-C6)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, SfCi-CgJhaloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-C6)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cg)alkyl, (C3-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cs)haloalkyl, (C3-Cgjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, SfCi-CgJhaloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-C6)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; r15 |S se|ected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cg)haloalkyl, (C2-C6)haloalkenyl, and (Ci-Cg) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R12 is selected from the group consisting of H, F, Cl, CH3 and CFa; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, 5 crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, 10 and (Ci-Cs) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFa; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; 15    R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VII) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein 5 R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R12 is H or F ; R13 is Cl or F ; 10    R14 is selected from the group consisting of H and F ; R15 is selected from the group consisting of H, and CH3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VII) R4 15 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; 5     R12 is H ; R13 is Cl; R14 is H; R15 is H. 10 In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VIII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, 15 wherein wherein R2, R3, R4, R12, R13, R14, and R15, are defined as elsewhere in this description. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VIII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cg)haloalkenyl, (C3-C6)halocycloalkenyl, (Ci-Cg)haloalkoxy, S(Ci-Cg)alkyl, S(O)(Ci-Cg)alkyl, S(O)2(Ci-Cs)alkyl, SfCi-CgJhaloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-C6)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, SfCi-CgJhaloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-C6)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cg)alkyl, (C3-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cs)haloalkyl, (C3-Cgjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, SfCi-CgJhaloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-C6)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; r15 |S se|ected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VIII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cg)haloalkyl, (C2-C6)haloalkenyl, and (Ci-Cg) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R12 is selected from the group consisting of H, F, Cl, CH3 and CFa; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VIII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, 5 crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, 10 and (Ci-Cs) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFa; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; 15    R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VIII) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein 5 R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R12 is H or F ; R13 is Cl or F ; 10    R14 is selected from the group consisting of H and F ; R15 is selected from the group consisting of H, and CH3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (VIII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; 5 R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; R12 is H ; R13 is Cl; R14 is H; 10    R15 is H. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IX) R4 15 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2, R3, R4, R12, R13, R14, and R15 are defined as elsewhere in this description. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IX) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cg)haloalkenyl, (C3-C6)halocycloalkenyl, (Ci-Cg)haloalkoxy, S(Ci-Cg)alkyl, S(O)(Ci-Cg)alkyl, S(O)2(Ci-Cs)alkyl, SfCi-CgJhaloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-C6)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, SfCi-CgJhaloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-C6)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cg)alkyl, (C3-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cs)haloalkyl, (C3-Cgjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, SfCi-CgJhaloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-C6)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; r15 |S se|ected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IX) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cg)haloalkyl, (C2-C6)haloalkenyl, and (Ci-Cg) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R12 is selected from the group consisting of H, F, Cl, CH3 and CFa; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IX) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, 5 crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, 10 and (Ci-Cs) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFa; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; 15    R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IX) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein 5 R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R12 is H or F ; R13 is Cl or F ; 10    R14 is selected from the group consisting of H and F ; R15 is selected from the group consisting of H, and CH3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (IX) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; R12 is H ; R13 is Cl; R14 is H; R15 is H. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (X) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2, R3, R4, R5, R6, R7, R8, R9 R12, R13, R14, R15, A2, A3, A4, and A5 are defined as elsewhere in this description and wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (X) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N ; wherein no more than 2 of A2, A3, A4, A5 are N or N=O; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-C6)alkyl, (C3-C6)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, CN, NO2, and =0; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Cgjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (C3-C6)halocycloalkenyl, (C3-C6)halocycloalkyl, (Ci-C6)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-Cs)alkyl)(Ci-Cs)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Cgjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-C6)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-C6)alkenyl, (C3-C6)cycloalkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, (C3-C6)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl; wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (X) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N; wherein no more than 2 of A2, A3, A4, A5 are N or N=O; R6 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -O-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN; R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, and CN; R9 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-C6)alkyl, (C2-Cg)alkenyl, (C2-Cg)haloalkenyl, and C(=O)-O-(Ci-Cg)alkyl; R10 is selected from the group consisting H, (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, ((Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl, and (Ci-C6)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFs; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, and Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (X) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein no more than 2 of A2, A3, A4, A5 are N; R6 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, and (Ci-Cs)haloalkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Cgjalkyl, F, and Cl; R8 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, and Cl; R9 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (X) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein 0 or 1 of A2, A3, A4, A5 are N; R6 is selected from the group consisting of H, F, NH(Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, and Cl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R8 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R9 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is H or F ; R13 is Cl or F ; R14 is selected from the group consisting of H and F ; R15 is selected from the group consisting of H, and CH3; wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (X) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; A2 is CRs or N; A3 is CR?; A4 is CRg; As is CRg; wherein 0 or 1 of A2 are N; R6 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R7 is selected from the group consisting of H, and F ; R8 is selected from the group consisting of H, and F ; R9 is selected from the group consisting of H and F ; R12 is H ; R13 is Cl; R14 is H; R15 is H wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XI) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2, R3, R4, R5, R6, R7, R8, R9 R12, R13, R14, R15, Ai, A3, A4, and A5 are defined as elsewhere in this description and wherein at least one of R5, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XI) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein Ai is CR5, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N ; wherein no more than 2 of Ai, A3, A4, A5 are N or N=O; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R5 is selected from the group consisting of H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci- C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)alkyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkenyl, (C3-Cs)halocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, C3-Cs)cycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-C6)-alkenyl, (Ci-C6)alkyl-(C3-C6)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (C3-Cs)cycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (C3-Cs)halocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (C3-Cs)cycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (C3-Cs)halocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (C3-Cs)cycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (C3-Cs)halocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci- Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl; wherein at least one of R5, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XI) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; Ai is CR5, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N; wherein no more than 2 of Ai, A3, A4, A5 are N or N=O; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, N(C1-C6)alkyl-C(=O)lR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, and CN; R9 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R10 is selected from the group consisting H, (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, ((Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl, and (Ci-C6)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFs; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R5, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, and Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XI) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-C6) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; Ai is CR5 or N; As is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein no more than 2 of Ai, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, NHC(=O)R10, and N(Ci-Cg)alkyl-C(=O)lR10; R7 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, and (Ci-Cs)haloalkyl; R8 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Ca)alkyl, F, and Cl; R9 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R5, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XI) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; Ai is CR5 or N; As is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein 0 or 1 of Ai, A3, A4, A5 are N; R5 is selected from the group consisting of H, F, Cl, CN, NO2, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R7 is selected from the group consisting of H, F, and Cl; R8 is selected from the group consisting of H, F, and NH(Ci-Cg)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R9 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is H or F ; R13 is Cl or F ; R14 is selected from the group consisting of H and F ; R15 is selected from the group consisting of H, and CH3; wherein at least one of R5, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XI) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; Ai is CR5 or N; A3 is CR?; A4 is CRg; As is CRg; wherein 0 or 1 of Ai are N; R5 is selected from the group consisting of H, F, Cl, CN and (Ci-Cs)alkyl; R7 is selected from the group consisting of H, and F ; R8 is selected from the group consisting of H, and F ; R9 is selected from the group consisting of H and F ; R12 is H ; R13 is Cl; R14 is H; R15 is H wherein at least one of R5, R7, R8, R9, is a substituent selected from the group consisting of F, and Cl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2, R3, R4, R13, R14, R15, are defined as elsewhere in this description. 10 In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, 15 wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cg)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cg)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XII) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein 5 R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R13 is Cl or F ; R14 is selected from the group consisting of H and F ; 10    R15 is selected from the group consisting of H, and CH3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, 15 crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; R13 is Cl; 5    R14 is H; R15 is H. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIII) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2, R3, R4,, R13, R14, R15, are defined as elsewhere in this description. 15 In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIII) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-C6)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-C6)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-C6)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, 5 crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2- C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-10 C6)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; 15    R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIII) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein 5 R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-C6) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, 10 (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. 15 In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIII) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R13 is Cl or F ; R14 is selected from the group consisting of H and F ; R15 is selected from the group consisting of H, and CH3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIII) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; R13 is Cl; R14 is H; R15 is H. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIV) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2, R3, R4, R13, R14, R15, are defined as elsewhere in this description. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIV) R4 H and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, 10 crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci- 15 Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (C3-Cg)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIV) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIV) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)aIkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIV) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein 5 R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R13 is Cl or F ; R14 is selected from the group consisting of H and F ; 10    R15 is selected from the group consisting of H, and CH3. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XIV) 15 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br; R3 is selected from the group consisting of H, F, Cl, Br, and I; R4 is selected from the group consisting of H, F, Cl, Br; 5     R13 is Cl; R14 is H; R15 is H. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a 10 compound of formula (XV) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2, R3, R4, R6, R7, R8, R9 R13, R14, R15, A2, A3, A4, and A5 are defined as elsewhere in this 15 description and wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XV) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N ; wherein no more than 2 of A2, A3, A4, A5 are N or N=O; R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5; R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-Cs)alkyl)(Ci-Cs)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-Cs)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci- C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-C6)cycloalkyl, (C3-C6)halocycloalkenyl, (C3-C6)halocycloalkyl, (Ci-C6)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Csjalkyl, F, Cl, Br, I, CN, NO2, and =0; R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Cgjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-Cs)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Cx-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0; R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (C3-Cs)cycloalkenyl, (C3-Cs)cycloalkyl, (C3-Cs)halocycloalkenyl, (C3-Cs)halocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-Cs)alkyl)(C(=O)O(Ci-Cs)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-Cs)alkylC(=O)(Ci-Cs)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-Cs)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl, wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl; R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Cgjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-Cs)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl; R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-Cs)cycloalkyl, (C2-Cs)alkenyl, (C3-Cs)cycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-C6)alkyl, S(O)2(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-C6)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl; R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-Cs)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2; R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkyl; wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XV) R4 H and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-C6)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C2-Cs)haloalkenyl, (Ci-Cs)haloalkoxy; A2 is CRs, N=O, or N; A3 is CR7, N=O, or N; A4 is CRg, N=O or N; A5 is CRg, N=O or N; wherein no more than 2 of A2, A3, A4, A5 are N or N=O; R6 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R7 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN; R8 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, and -0-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, and CN; R9 is selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NH2, =0, NH(Ci-Cs)alkyl, N((Ci-C6)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-C6)haloalkyl, NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10, C(=O)(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)haloalkenyl, and C(=O)-O-(Ci-Cs)alkyl; R10 is selected from the group consisting H, (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, ((Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, tetrahydrothiophenyl, thianyl, phenyl, and (Ci-C6)alkylphenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CFs; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, and Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XV) R4 and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy; R4 is selected from the group consisting of H, F, Cl, Br, I, CN, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, and (C2-Cs)haloalkenyl; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein no more than 2 of A2, A3, A4, A5 are N; R6 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, (Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-C6)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, N((Ci-Cs)alky)2, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and (Ci-Cs)haloalkyl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, and Cl; R8 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-Cgjalkyl, F, and Cl; R9 is selected from the group consisting of H, F, Cl, NH(Ci-Cs)alkyl, and (Ci-Cs)alkyl; R10 is selected from the group consisting (Ci-Cs)alkyl, (Ci-Cs)alkyloxy-(Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, tetrahydrofuranyl, and phenyl; R12 is selected from the group consisting of H, F, Cl, CH3 and CF3; R13 is selected from the group consisting of H, F, Cl, CH3 and CF3; R14 is selected from the group consisting of H, F, Cl, CH3 and CF3; R15 is selected from the group consisting of H, CH3, and CF3; wherein at least one of R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I. In an embodiment of the invention and / or embodiments thereof, the invention is directed to a compound of formula (XV) and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof, wherein R2 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; R3 is selected from the group consisting of H, F, Cl, Br, I, (Ci-Cs)haloalkyl, and (Ci-Cs) haloalkoxy ; R4 is selected from the group consisting of H, F, Cl, Br, (Ci-Cs)alkyl, and (Ci-Cs)haloalkyl; A2 is CRsor N; A3 is CR7 or N; A4 is CRg or N; A5 is CRg or N; wherein 0 or 1 of A2, A3, A4, A5 are N; R6 is selected from the group consisting of H, F, NH(Ci-Cs)alkyl, NHC(=O)R10, and N(Ci-Cs)alkyl-C(=O)IR10; R7 is selected from the group consisting of H, F, and Cl; or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of CH3, F, and Cl; R8 is selected from the group consisting of H, F, and NH(Ci-Cs)alkyl; or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, and -NH-, wherein the ring formed by R7 and...

Claims

1. A Compound of Formula (I)R4Formula (I)and N-oxides, veterinary acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystal polymorphs, isotopes, stereoisomers, and tautomers thereof,for use in a method of treatment or control of a parasitic infestation of an animal, whereinAi is CR5, N=O, or N;A2 is CRs, N=O, or N;A3 is CR7, N=O, or N;A4 is CRg, N=O or N;A5 is CRg, N=O or N;wherein no more than 3 of Ai, A2, A3, A4, As are N or N=O;R1 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Csjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2;R2 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2 and S-(Halo)5;R3 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5;R4 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Csjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(O)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-Cs)haloalkyl-S(O)2NH2 and S-(Halo)5;R5 is selected from the group consisting of H, F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl,wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl;R6 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-Cs)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl,wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl;R7 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-C6)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(Ci-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(0)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)al kyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(0)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl,wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl;R8 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-C6)alkylphenyl, (Ci-C6)alkyl-S(O)2NH2, (Ci-C6)haloalkoxy, (Ci-C6)haloalkyl, (Ci-Cs)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-Cs)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(CX-C6)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl,wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-C6)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-Cs)haloalkyl, NHCH2(C3-Cs)cycloalkyl, NH2, NO2, oxo, (Ci-Cs)alkyl, (Ci-C6)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl;R9 is selected from the group consisting of F, Cl, Br, I, H, CN, CHO, NHOH, NO, NO2, OH, NH2, =0, (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-Cs)alkylphenyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkoxy, (Ci-Cs)haloalkyl, (Ci-C6)haloalkyl-S(O)2NH2, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (C2-Cs)haloalkenyl, (Cs-Csjcycloalkenyl, (C3-C6)cycloalkyl, (Cs-Csjhalocycloalkenyl, (Cs-Csjhalocycloalkyl, (Ci-Cs)alkyl((Ci-Cs)alkyl)(=NO(Ci-Cs)alkyl), C(=NO(Ci-C6)alkyl)(Ci-C6)alkyl, C(=O)(Ci-C6)alkyl, C(=O)NH(Ci-C6)alkyl, C(=O)NHphenyl, C(=O)O(Ci-C6)alkyl, CH(=NO(Ci-Cs)alkyl), imidazolyl, N((Ci-Cs)alkyl)(C(=O)(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)alkyl-O(Ci-C6)alkyl), N((Ci-C6)alkyl)(C(=O)(Ci-C6)haloalkyl), N((Ci-C6)alkyl)(C(=O)O(Ci-C6)alkyl), N((Ci-C6)alkyl)2, N(C(=O)O(Ci-C6)alkyl)2, N=CH-phenyl, NH((Ci-C6)alkylC(=O)(Ci-C6)alkyl), NHC(=O)R10, N(CX-Cs)alkyl-C(=O)IR10 NH(Ci-Cs)alkyl, NH(Ci-Cs)alkenyl, NH(Ci-Cs)alkynyl, NH(Ci-Cs)alkylphenyl, NH(S(O)2(Ci-Cs)alkyl), NH-C(=O)O(Ci-Cs)alkyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, S(=NCN)((Ci-C6)alkyl), S(Ci-C6)alkyl, S(Ci-C6)haloalkyl, S(O)(=NCN)((Ci-C6)alkyl), S(O)(Ci-C6)al kyl, S(O)(Ci-C6)haloalkyl, S(O)2(Ci-Cs)alkyl, S(O)2(Ci-Cs)haloalkyl, SCN, thiazolyl, thienyl, and triazolyl,wherein each alkoxy, alkyl, haloalkoxy, haloalkyl, alkenyl, alkynyl, haloalkenyl, cycloalkenyl, cycloalkyl, halocycloalkenyl, halocycloalkyl, imidazolyl, phenyl, pyrazolyl, pyridinyl, thiazolyl, thienyl, and triazolyl, may be optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, OH, NH(Ci-Cs)alkyl, NH(C3-Cs)cycloalkylCH2O(Ci-Cs)alkyl, NH(C3-C6)cycloalkylCH2O(Ci-C6)haloalkyl, NHCH2(C3-C6)cycloalkyl, NH2, NO2, oxo, (Ci-C6)alkyl, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, and C(=O)O-(Ci-Cs)alkyl;or R6 and R7 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -O-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R6 and R7 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0;or R7 and R8 together with the atoms to which they are attached form a 5 or 6- atoms containing ring, wherein the ring-forming atoms are selected from the group consisting of -CH2-, -CH=, =CH-,-N=, =N-, -NH-, -0-, -S(O)-, -S(O)2- and -S-, wherein the ring formed by R7 and R8 is optionally substituted with one or more substituents of selected from the group consisting of (Ci-C3)alkyl, F, Cl, Br, I, CN, NO2, and =0;R10 is selected from the group consisting of H, (Ci-Cs)alkyl, Cs-Cgjcycloalkyl), (Ci-Cs)alkyloxy-(Ci-Cs)-alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl, (Ci-Cs)alkyloxy-(Ci-Cs)haloalkyl, Ci-Cs)alkyloxy-(C2-Cs)-alkenyl, (Ci-Cs)alkyl-(C3-Cs)cycloalkyl, heterocycle, aryl and (Ci-Cs)alkylphenyl;R11 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cg)alkyl, (C3-Cg)cycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2;R12 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2;R13 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, CHO, (Ci-Cs)alkyl, (C3-C6)cycloalkyl, (C2-Cs)alkenyl, (Cs-Csjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (C3-C6)halocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, (Ci-Cs)haloalkyl-S(O)2NH2, and triazolyl;R14 is selected from the group consisting of H, F, Cl, Br, I, CN, NH2, NO2, (Ci-Cs)alkyl, (Cs-Cgjcycloalkyl, (C2-Cs)alkenyl, (Cs-Cgjcycloalkenyl, (C2-Cs)alkynyl, (Ci-Cs)alkoxy, (Ci-Cs)haloalkyl, (Cs-Csjhalocycloalkyl, (C2-Cs)haloalkenyl, (Cs-Cgjhalocycloalkenyl, (Ci-Cs)haloalkoxy, S(Ci-Cs)alkyl, S(O)(Ci-Cs)alkyl, S(0)2(Ci-Cs)alkyl, S(Ci-Cs)haloalkyl, S(O)(Ci-Cs)haloalkyl, S(O)2(Ci-Cs)haloalkyl, (Ci-Cs)alkyl-S(O)2NH2, and (Ci-C6)haloalkyl-S(O)2NH2;R15 is selected from the group consisting of H, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy(Ci-Cs)alkyl, C(=O)(Ci-Cs)alkyl, and (Ci-Cs)alkoxyC(=O)(Ci-Cs)alkylH, (Ci-Cs)alkyl, (C2-Cs)alkenyl, (C2-Cs)alkynyl, (Ci-Cs)haloalkyl;wherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I.

2. A compound or use according to any of the preceding claims, wherein at least two of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I, more preferably F or Cl.

3. A compound or use according to any of the preceding claims, wherein 1 of Ai, A2, A3, A4, A5 is N, preferably Ai or A2 is N.

4. A compound or use according to any of the preceding claims, wherein R12 is selected from the group consisting H, F, CL, CH3, CF3.

5. A compound or use according to any of the preceding claims, wherein R13 is selected from the group consisting of H, F, Cl, CF3 and CH3.

6. A compound or use according to any of the preceding claims, wherein R15 is selected from the group consisting of H and CH3.

7. A compound or use according to any of the preceding claims, wherein at least one of the following selections is made:R1 is selected from the group consisting of H F, and Cl; and / orR2 is selected from the group consisting of H, F, and Cl; and / orR3 is selected from the group consisting of H, F, and Cl; and / R4 is selected from the group consisting of H, F, and Cl.

8. A compound or use according to any of the preceding claims, wherein at least one of the following selections is made:R5 is selected from the group consisting of H F, Cl, Br, and I; and / orR6 is selected from the group consisting of H, F, and Cl, Br, and CH3; and / orR7 is selected from the group consisting of H F, Cl, Br, and I; and / orR8 is selected from the group consisting of H, F, Cl, and Br, and CH3; and / orR9 is selected from the group consisting of H F, Cl, Br, and I.

9. A compound or use according to any of the preceding claims, wherein:R1 is selected from the group consisting of H F, and Cl;R2 is selected from the group consisting of H, F, and Cl;R3 is selected from the group consisting of H, F, and Cl;R4 is selected from the group consisting of H, F, and Cl;R5 is selected from the group consisting of H F, Cl, Br, and I;R6 is selected from the group consisting of H, F, and Cl, Br, and CH3;R7 is selected from the group consisting of H F, Cl, Br, and I;R8 is selected from the group consisting of H, F, Cl, and Br, and CH3;R9 is selected from the group consisting of H F, Cl, Br, and I;R11 is H;R12 is selected from the group consisting H, F, CL, CH3, CF3;R13 is selected from the group consisting of H, F, Cl, CF3 and CH3;R14 is H or F;R15 is selected from the group consisting of H and CH3; andwherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I.

10. A compound and use according to any of the preceding claims, wherein:R1 is H;R2 is selected from the group consisting of H, F, and Cl;R3 is selected from the group consisting of H, Cl, F, and Br;R4 is H, F, Cl;R5 is selected from the group consisting of H F, and Cl;R6 is selected from the group consisting of H, F, and Cl, and CH3;R7 is selected from the group consisting of H F, and Cl;R8 is selected from the group consisting of H, F, Cl, and CH3;R9 is selected from the group consisting of H F, and Cl;R11 is H;R12 is selected from the group consisting H, F and Cl;R13 is selected from the group consisting of H, F, and Cl;R14 is H;R15 is selected from the group consisting of H and CH3; andwherein at least one of R5, R6, R7, R8, R9, is a substituent selected from the group consisting of F, Cl, Br, and I.

11. Compound for use according to any of the preceding claims, wherein the parasitic infestation is an ectoparasite infestation.

12. Compound for use according to any of the preceding claims, wherein the parasitic infestation is an acaracide infestation.

13. Compound for use according to any of the preceding claims, wherein the parasitic infestation is an infestation selected from tick, flea and / or fly, preferably a tick infestation.

14. Compound for use according to any of the preceding claims, wherein the parasite is a one host tick or a multi-host tick, preferably the parasite is Rhipicephalus microplus.

15. Compound for use according to any of the preceding claims, wherein the animal is a warmblooded animal, especially a mammal.

16. Compound for use according to any of the claims 1-15, wherein the animal is a livestock animal, especially ruminant, especially a bovine animal, especially cattle.

17. Compound for use according to any of the claims 1-15, wherein the animal is a fish, and the parasitic infestation is a sea lice infestation.

18. Compound for use according to any of claims 1-15, wherein the animal is a companion animal, especially canine animal or a feline animal, especially a dog or cat.

19. Compound for use according to any of the preceding claims, wherein the animal is protected from a parasite infestation.

20. Compound for use according to any of the preceding claims, wherein an existing parasite infestation of the animal is treated or controlled.

21. Compound for use according to any of the preceding claims, wherein the method comprises administering the compound to an animal weekly, bi-weekly, monthly, every 6 weeks, every 2 months, every 3 months, 6 months or 9 months.

22. A veterinary composition comprising an effective amount of a compound of Formula (I) as defined in any of claims 1-10 and an inert carrier or formulation adjuvant.

23. The veterinary composition according to claim 22, wherein the veterinary composition is a topical composition, an oral composition, or an injection composition.

24. The veterinary composition according to claim 21 or 22 and a pharmaceutically acceptable oily carrier.

25. The veterinary composition according to claim 24 wherein the oily carrier comprises a fatty acid ester, preferably essentially consist of a fatty acid ester.

26. The veterinary pharmaceutical composition according to claim 25, wherein the fatty acid ester is a glycol diester or a glycerol triester of a Cg-io fatty acid, preferably propylene glycol octanoate decanoate (e.g. Miglyol 840).

27. The veterinary pharmaceutical composition according to claim 25, wherein the oily carrier comprises a combination of glycerol monocaprylate and propylene glycol dicaprylocaprate.5   28. The veterinary pharmaceutical composition according to any one of claims 22 to 27, wherein thecomposition does not comprise a penetration enhancer.

29. The veterinary pharmaceutical composition according to any one of claims 22 to 28, comprising:a) from about 0.5% to about 10% w / v, preferably 1% of the compound of Formula (I);10 bl) from about 90% to 99.9% w / v of preferably propylene glycol octanoate decanoate; or alternativelyb2) from about 10% to about 40% w / v, preferably 20% of glycerol monocaprylate; andc) optionally from about 2% to about 50% w / v, preferably 99% of propylene glycol dicaprylocaprate.

Images